Concurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for prostate cancer.
Patients receiving any other concurrent anticancer or investigational therapy
Concurrent anticancer therapy; however, radiotherapy is allowed
Concurrent therapy: no other concurrent anticancer or investigational therapy permitted except as noted above
No other concurrent anticancer therapy or prior prostate cancer vaccines expressing TARP
Concurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for breast or prostate cancer; patients that have received treatment for a different cancer previously and have been disease-free for less than one year are excluded
Concurrent therapy with approved or investigational anticancer therapeutics.
No concurrent therapy with approved or investigational anticancer therapeutics
Prior or concurrent treatment with any anticancer agent for the same cancer diagnosis
Any concurrent anticancer therapy
Concurrent treatment with any other anticancer therapy
Concurrent use of conventional or investigational anticancer agents, except hydroxyurea
Concurrent anticancer therapy (including other investigational agents)
Plans for concurrent anticancer therapy except as permitted
Concurrent use of other anticancer approved or investigational agents is not allowed.
Concurrent therapy with approved or investigational anticancer therapy
No concurrent anticancer chemotherapy or local therapy
No other concurrent anticancer therapy
Concurrent anticancer treatment within 28 days before the start of trial treatment
Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
Concurrent treatment with any other anticancer therapy
Concurrent use of other anticancer approved or investigational agents is not allowed.
Concurrent anticancer treatment or immunosuppressive agents
SUB-PROTOCOL AIM A: Concurrent use of any other approved or investigational anticancer agents which would be considered as a treatment for the primary neoplasm
Concurrent therapy with any other investigational anticancer agent
Concurrent treatment with any anticancer agent outside of this protocol
Concurrent therapy with approved or investigational anticancer therapeutic
Concurrent therapy with approved or investigational anticancer therapeutic
Concurrent anticancer therapy or any cytotoxic therapy within 1 month prior to Day 1. Corticosteroid therapy is not allowed except on dosing days;
Other concurrent anticancer therapies.
No other concurrent anticancer therapies or agents
Any concurrent anticancer therapy, excluding hormonal therapy for prostate or breast cancer
Concurrent treatment with any other anticancer therapy
Concurrent anticancer therapy (including other investigational agents), with the exception of hormone therapy for prostate cancer
Patients must not be receiving other investigational agents or concurrent anticancer therapy
No other concurrent anticancer agents
Other concurrent anticancer chemotherapy
Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
Concurrent anticancer therapy
Concurrent chronic immunosuppressive or hormone anticancer therapy (except other physiologic hormone replacement)
Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
Concurrent treatment with other anticancer therapy
Receiving concurrent treatment with other anticancer therapy
Concurrent anticancer therapy (including other investigational agents)
Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
Concurrent therapy with approved or investigational anticancer therapeutics